MX2020008767A - Disruptores del dímero egfr y uso de estos. - Google Patents
Disruptores del dímero egfr y uso de estos.Info
- Publication number
- MX2020008767A MX2020008767A MX2020008767A MX2020008767A MX2020008767A MX 2020008767 A MX2020008767 A MX 2020008767A MX 2020008767 A MX2020008767 A MX 2020008767A MX 2020008767 A MX2020008767 A MX 2020008767A MX 2020008767 A MX2020008767 A MX 2020008767A
- Authority
- MX
- Mexico
- Prior art keywords
- same
- disruptors
- egfr dimer
- egfr
- dimer
- Prior art date
Links
- 108060006698 EGF receptor Proteins 0.000 title 1
- 239000000539 dimer Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862634452P | 2018-02-23 | 2018-02-23 | |
| PCT/US2019/019391 WO2019165358A1 (en) | 2018-02-23 | 2019-02-25 | Egfr dimer disruptors and use of the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020008767A true MX2020008767A (es) | 2021-01-08 |
Family
ID=67688515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020008767A MX2020008767A (es) | 2018-02-23 | 2019-02-25 | Disruptores del dímero egfr y uso de estos. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11358965B2 (https=) |
| EP (1) | EP3755323A4 (https=) |
| JP (2) | JP7497046B2 (https=) |
| KR (1) | KR102748047B1 (https=) |
| CN (1) | CN111886009A (https=) |
| AU (1) | AU2019223168B2 (https=) |
| BR (1) | BR112020017184A2 (https=) |
| CA (1) | CA3091834A1 (https=) |
| EA (1) | EA202092000A1 (https=) |
| MX (1) | MX2020008767A (https=) |
| WO (1) | WO2019165358A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3091834A1 (en) * | 2018-02-23 | 2019-08-29 | The Regents Of The University Of Michigan | Egfr dimer disruptors and use of the same |
| CN114286676A (zh) * | 2019-08-22 | 2022-04-05 | 密歇根大学董事会 | 治疗kras相关癌症的方法 |
| CA3172812A1 (en) * | 2020-03-05 | 2021-09-10 | The Regents Of The University Of Michigan | Inhibitors of egfr, kras, braf, and other targets and use of the same |
| MX2022010977A (es) * | 2020-03-05 | 2022-12-02 | Univ Michigan Regents | Inhibidores de egfr, kras, braf y otros objetivos y uso de los mismos. |
| IL301532A (en) | 2020-09-23 | 2023-05-01 | Scorpion Therapeutics Inc | History Pyrrolo[2,3-C]pyridin-4-one is useful in cancer treatment |
| WO2022072632A1 (en) | 2020-09-30 | 2022-04-07 | Scorpion Therapeutics, Inc. | Bicyclic compounds for use in the treatment cancer |
| WO2022072645A2 (en) | 2020-09-30 | 2022-04-07 | Scorpion Therapeutics, Inc. | Methods for treating cancer |
| TW202229282A (zh) | 2020-09-30 | 2022-08-01 | 美商史考皮恩治療有限公司 | 治療癌症之方法 |
| BR112023006531A2 (pt) | 2020-10-09 | 2023-10-03 | Scorpion Therapeutics Inc | Inibidores heterocílicos de egfr e/ou her2, para uso no tratamento de câncer |
| EP4225304B1 (en) * | 2020-10-12 | 2025-12-17 | The Regents of The University of Michigan | Synthesis of egfr modulators |
| WO2022077154A1 (en) * | 2020-10-12 | 2022-04-21 | The Regents Of The University Of Michigan | Synthesis of egfr modulators |
| WO2022094271A1 (en) | 2020-10-30 | 2022-05-05 | Scorpion Therapeutics, Inc. | Methods for treating cancer |
| WO2022098992A1 (en) | 2020-11-05 | 2022-05-12 | Scorpion Therapeutics, Inc. | Use of macrocyclic compounds in methods of treating cancer |
| WO2022197913A1 (en) | 2021-03-18 | 2022-09-22 | Scorpion Therapeutics, Inc. | Bicyclic derivatives which can be used to treat cancer |
| EP4323356A1 (en) | 2021-04-13 | 2024-02-21 | Nuvalent, Inc. | Amino-substituted heterocycles for treating cancers with egfr mutations |
| WO2023173083A1 (en) | 2022-03-11 | 2023-09-14 | Scorpion Therapeutics, Inc. | Tetrahydroindole derivatives as egfr and/or her2 inhibtors useful for the treatment of cancer |
| CN121909190A (zh) | 2023-06-08 | 2026-04-21 | 安塔列斯疗法股份有限公司 | 1,5-二氢-4H-吡咯并[3,2-c]吡啶-4-酮用于癌症治疗 |
| CN121712773A (zh) | 2023-06-08 | 2026-03-20 | 安塔列斯疗法股份有限公司 | 1,5-二氢-4h-吡咯并[3,2-c]吡啶-4-酮用于癌症治疗 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3547977A (en) | 1967-10-27 | 1970-12-15 | Velsicol Chemical Corp | Novel carbanilates |
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| CA2709784A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| WO2012087943A2 (en) | 2010-12-20 | 2012-06-28 | The Regents Of The University Of Michigan | Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction |
| WO2014176475A2 (en) * | 2013-04-26 | 2014-10-30 | The Regents Of The University Of Michigan | Egfr inhibitors and uses thereof |
| US9499551B2 (en) * | 2014-01-24 | 2016-11-22 | Confluence Life Sciences, Inc. | Substituted pyrrolo[2,3-b]pyridines for treating cancer or inflammatory diseases |
| CN113563332B (zh) * | 2014-12-23 | 2024-12-17 | 达纳－法伯癌症研究所公司 | 作为egfr抑制剂的新的嘧啶和治疗病症的方法 |
| CA3091834A1 (en) | 2018-02-23 | 2019-08-29 | The Regents Of The University Of Michigan | Egfr dimer disruptors and use of the same |
-
2019
- 2019-02-25 CA CA3091834A patent/CA3091834A1/en active Pending
- 2019-02-25 EP EP19757355.3A patent/EP3755323A4/en active Pending
- 2019-02-25 MX MX2020008767A patent/MX2020008767A/es unknown
- 2019-02-25 WO PCT/US2019/019391 patent/WO2019165358A1/en not_active Ceased
- 2019-02-25 US US16/970,655 patent/US11358965B2/en active Active
- 2019-02-25 KR KR1020207027147A patent/KR102748047B1/ko active Active
- 2019-02-25 EA EA202092000A patent/EA202092000A1/ru unknown
- 2019-02-25 CN CN201980020234.3A patent/CN111886009A/zh active Pending
- 2019-02-25 JP JP2020544510A patent/JP7497046B2/ja active Active
- 2019-02-25 AU AU2019223168A patent/AU2019223168B2/en active Active
- 2019-02-25 BR BR112020017184-0A patent/BR112020017184A2/pt unknown
-
2022
- 2022-05-09 US US17/739,358 patent/US11999731B2/en active Active
-
2024
- 2024-01-25 JP JP2024009496A patent/JP2024056735A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200124709A (ko) | 2020-11-03 |
| BR112020017184A2 (pt) | 2020-12-22 |
| EA202092000A1 (ru) | 2020-12-09 |
| US20200377503A1 (en) | 2020-12-03 |
| WO2019165358A1 (en) | 2019-08-29 |
| AU2019223168A1 (en) | 2020-09-10 |
| CN111886009A (zh) | 2020-11-03 |
| US20220340572A1 (en) | 2022-10-27 |
| EP3755323A1 (en) | 2020-12-30 |
| AU2019223168B2 (en) | 2024-09-12 |
| JP7497046B2 (ja) | 2024-06-10 |
| EP3755323A4 (en) | 2021-11-24 |
| JP2024056735A (ja) | 2024-04-23 |
| US11999731B2 (en) | 2024-06-04 |
| CA3091834A1 (en) | 2019-08-29 |
| US11358965B2 (en) | 2022-06-14 |
| KR102748047B1 (ko) | 2024-12-27 |
| JP2021514001A (ja) | 2021-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020008767A (es) | Disruptores del dímero egfr y uso de estos. | |
| MX2020012797A (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso. | |
| EA201992497A1 (ru) | МОДУЛЯТОРЫ K-Ras | |
| MX392368B (es) | Composiciones y metodos para el tratamiento del cancer | |
| MX394380B (es) | Compuestos dinucleótidos cíclicos para eltratamiento de cáncer | |
| EP4302835A3 (en) | Methods of treating ovarian cancer | |
| MX2018008426A (es) | Combinaciones anti-egfr para tratar tumores. | |
| PH12020500576A1 (en) | Method of treating cancers with antagonistic anti-pd-1 antibodies | |
| PH12020500371A1 (en) | Spirocycle compounds and methods of making and using same | |
| TW201613647A (en) | Compounds and compositions for treating HER2 positive tumors | |
| EA201792443A1 (ru) | МОДУЛЯТОРЫ K-Ras | |
| MX2018001954A (es) | Diacuerpos monovalentes biespecificos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos. | |
| PH12017501748B1 (en) | Antibodies to icos | |
| MX2018016038A (es) | Compuestos y metodos para modular la funcion del acido ribonucleico (arn). | |
| PH12022550646A1 (en) | Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use | |
| EA201790921A1 (ru) | Замещенные производные 2-анилинпиримидина в качестве модуляторов egfr | |
| PH12016502607A1 (en) | Functionalised and substituted indoles as anti-cancer agents | |
| MX2017010595A (es) | Métodos, composiciones, y equipos para tratamiento de cáncer. | |
| PH12020500372A1 (en) | Spirocycle compounds and methods of making and using same | |
| AU2016246521A8 (en) | Treatment of lung cancer with inhibitors of glutaminase | |
| MX2022007955A (es) | Regimenes de dosificacion de erdafitinib. | |
| MX2024012294A (es) | RECEPTORES DE TGF-ß Y MÉTODOS DE USO | |
| MX379271B (es) | Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cáncer. | |
| MX2020009902A (es) | Anticuerpos con especificidad dual para pd-l1 y pd-l2 humanos y metodos de uso de los mismos. | |
| MX2019008233A (es) | Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral. |